Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia

Marie E. Faughnan, James R Gossage, Murali M. Chakinala, S. Paul Oh, Raj Kasthuri, Christopher C.W. Hughes, Justin P. McWilliams, Joseph G. Parambil, Nicholas Vozoris, Jill Donaldson, Gitanjali Paul, Pamela Berry, Dennis L. Sprecher

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

Pazopanib (Votrient) is an orally administered tyrosine kinase inhibitor that blocks VEGF receptors potentially serving as anti-angiogenic treatment for hereditary hemorrhagic telangiectasia (HHT). We report a prospective, multi-center, open-label, dose-escalating study [50 mg, 100 mg, 200 mg, and 400 mg], designed as a proof-of-concept study to demonstrate efficacy of pazopanib on HHT-related bleeding, and to measure safety. Patients, recruited at 5 HHT Centers, required ≥ 2 Curacao criteria AND [anemia OR severe epistaxis with iron deficiency]. Co-primary outcomes, hemoglobin (Hgb) and epistaxis severity, were measured during and after treatment, and compared to baseline. Safety monitoring occurred every 1.5 weeks. Seven patients were treated with 50 mg pazopanib daily. Six/seven showed at least 50% decrease in epistaxis duration relative to baseline at some point during study; 3 showed at least 50% decrease in duration during Weeks 11 and 12. Six patients showed a decrease in ESS of > 0.71 (MID) relative to baseline at some point during study; 3/6 showed a sustained improvement. Four patients showed > 2 gm improvement in Hgb relative to baseline at one or more points during study. Health-related QOL scores improved on all SF-36 domains at Week 6 and/or Week 12, except general health (unchanged). There were 19 adverse events (AE) including one severe AE (elevated LFTs, withdrawn from dosing at 43 days); with no serious AE. In conclusion, we observed an improvement in Hgb and/or epistaxis in all treated patients. This occurred at a dose much lower than typically used for oncologic indications, with no serious AE. Further studies of pazopanib efficacy are warranted.

Original languageEnglish (US)
Pages (from-to)145-155
Number of pages11
JournalAngiogenesis
Volume22
Issue number1
DOIs
Publication statusPublished - Feb 15 2019

    Fingerprint

Keywords

  • Anemia
  • Epistaxis
  • Hereditary
  • Telangiectasia
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Physiology
  • Clinical Biochemistry
  • Cancer Research

Cite this

Faughnan, M. E., Gossage, J. R., Chakinala, M. M., Oh, S. P., Kasthuri, R., Hughes, C. C. W., ... Sprecher, D. L. (2019). Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia. Angiogenesis, 22(1), 145-155. https://doi.org/10.1007/s10456-018-9646-1